Canada’s biotech carpe diem
It’s imperative Canada keep pace with other competing jurisdictions, and establish itself as a regulatory leader that rewards investment and talent.
Harnessing the power of Canada’s growing biotechnology industry: a perspective from the West
Government investment and policy can help ensure groundbreaking technologies remain in Canada when companies scale up their production especially for international distribution.
Biotechnology: an opportunity balanced on a knife’s edge
To fully harness the benefits of a thriving biotechnology industry, it is critical we act to address the challenges that threaten it.
Does Canada need a more integrated strategy for pandemic responses? Yes
In the last 20 years, Canada has been hit by several health crises involving variants on known human pathogens and novel viruses arising from animal-to-human transmission. Our sense is that a wider-angle approach in some form merits very serious consideration to better protect Canadians in the next health emergency.
Canada’s biomedical brain drain is reversing. Let’s continue that trend
We must look beyond the lab and build a thriving ecosystem to make sure Canadian biomedical treatments are developed here and benefit Canadians.
Talent shortage a priority for biotech sector emerging from pandemic
Canada is likely to face a shortfall of about 65,000 workers in the bio-economy by 2029, according to BioTalent Canada.
Biotech Policy Briefing
Canada’s place in the world of biotechnology research and application is in jeopardy
Government of Canada funded scholarships and fellowships are the primary sources of income for many biotechnology researchers. To stem the brain-drain, Canada must significantly increase the value and number of graduate student scholarships and post-doctoral fellowships and to index them to the cost of living.
Can biotechnology put patients’ needs ahead of profits?
These are challenging dilemmas for a government that gutted a suite of policies designed to cap excessive drug prices, and that ‘waxed lyrical’ about the importance of accelerating vaccine access worldwide, then failed to support an intellectual property waiver that would expand global production of COVID-19 vaccines.
Seizing the moment: building Canada’s academic leadership into a commercial powerhouse
Too much high-quality research is failing to make it out of laboratories to the benefit of patients and the Canadian economy.
